Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00254202
Recruitment Status : Completed
First Posted : November 15, 2005
Last Update Posted : July 20, 2012
Information provided by:
Vanda Pharmaceuticals

Brief Summary:
The purpose of this study is to determine the safety and efficacy of iloperidone compared to placebo and an active comparator in the treatment of patients with schizophrenia in acute exacerbation.

Condition or disease Intervention/treatment Phase
Schizophrenia Drug: iloperidone Drug: active comparator Drug: placebo Phase 3

Detailed Description:

Schizophrenia is a severe mental illness affecting an estimated 1% of the world's population. Patients with schizophrenia suffer from productive symptoms (e.g., hallucinations and delusions), and deficit symptoms (e.g., a reduction or absence of normal behaviors or emotions). Other symptoms include a reduced ability to recall and learn new information.

Iloperidone is being development as a treatment for symptoms of schizophrenia. This trial will test the safety and efficacy of iloperidone in patients with an acute exacerbation of the disease.

Study Type : Interventional  (Clinical Trial)
Enrollment : 600 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Iloperidone in Schizophrenic Patients in Acute Exacerbation Followed by a Long-term Treatment Phase.
Study Start Date : November 2005
Actual Primary Completion Date : September 2006
Study Completion Date : March 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia
Drug Information available for: Iloperidone

Primary Outcome Measures :
  1. Positive and Negative Symptom Scale (PANSS) - Total Score

Secondary Outcome Measures :
  1. Pharmacogenetic analysis

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject with schizophrenia.
  • Subject must sign a written consent form.

Exclusion Criteria:

  • Clinically significant disease of the heart, kidneys, liver or gastrointestinal system
  • Psychiatric disorder other than schizophrenia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00254202

  Show 42 Study Locations
Sponsors and Collaborators
Vanda Pharmaceuticals

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00254202     History of Changes
Other Study ID Numbers: VP-VYV-683-3101
First Posted: November 15, 2005    Key Record Dates
Last Update Posted: July 20, 2012
Last Verified: July 2012

Keywords provided by Vanda Pharmaceuticals:
Atypical antipsychotic

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders